author-photo

Rahima Jamal

Université de Montréal

37

Papers

1409

Citations

Citation Trend

Filter By

Papers (31) Sort By

Journal Conference Others

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.

2021 The Lancet Respiratory Medicine
Show All
- Source
- Cite
- Save
Citations (59)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Development of a HLA-B*58:01 Allele Screening System for Allopurinol-Induced Severe Cutaneous Adverse Reactions Detection

2020 IEEE Access
Show All
- Source
- Cite
- Save
Citations (0)
Initial analyses of a phase I/II trial of durvalumab (D) plus tremelimumab (T) and stereotactic body radiotherapy (SBRT) for oligometastatic head and neck carcinoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

2020 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (125)
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.

2020 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (2)
Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy for oropharyngeal carcinomas.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (11)